Monday - May 5, 2025

LOGIN  |  REGISTER

Integer Releases Inaugural Impact Report

August 01, 2024 | Last Trade: US$125.66 0.07 0.06
  • Report Highlights Integer’s Commitment to Minimizing Environmental Footprint,
  • Maximizing Positive Global Impact and Enhancing the Lives of Patients Worldwide 

PLANO, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced the release of its first environmental, social and governance (ESG) report, “Making a Difference: Integer’s Inaugural Impact Report.”

“I am excited to introduce Integer’s first Impact Report,” said Joseph Dziedzic, Integer president and CEO. “At Integer, we are focused on strengthening our business in a way that minimizes our environmental footprint while ultimately advancing the future of medical devices and maximizing the positive impact we have on our associates, partners, patients who use our products, and the communities where we live and work around the world.”

The report highlights Integer’s efforts and progress in the areas of health and safety, diversity and inclusion, associate engagement, charitable initiatives and associate volunteerism, along with a range of other topics.

“From the life-enhancing work our more than 11,000 associates safely perform on four continents daily, to our strong partnerships with our customers and communities, we are committed to making a difference in the lives of patients worldwide,” said McAlister Marshall, Integer senior vice president and general counsel. “This inaugural Integer Impact Report seeks to further define that impact by highlighting our strategy, approach and corresponding progress in the environmental, social and governance space.”

The full Integer Impact Report can be found here.

Learn more about Integer at www.integer.net.

About Integer®

Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.

Investor Relations:Media Relations:
Andrew SennKelly Butler
andrew.senn@integer.netkelly.butler@integer.net
763.951.8312469.731.6617

Terns Pharmaceuticals

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page